Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 257

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Mycophenolate Mofetil for Ocular Inflammation

Open access
Daniel, Ebenezer, Thorne, Jennifer E., Newcomb, Craig W., Pujari, Siddharth S., Kaçmaz, R. Oktay, Levy-Clarke, Grace A., Nussenblatt, Robert B., Rosenbaum, James T., Suhler, Eric B., Foster, C. Stephen, Jabs, Douglas A., Kempen, John H.·2010·American Journal of Ophthalmology

Abstract

PURPOSE To evaluate mycophenolate mofetil as a single noncorticosteroid immunosuppressive treatment for noninfectious ocular inflammatory diseases. DESIGN Retrospective cohort study. METHODS Characteristics of patients with noninfectious ocular inflammation treated with mycophenolate mofetil at 4 subspecialty clinics from 1995 to 2007 were abstracted by expert reviewers in a standardized chart review of every eye at every visit. Main outcomes measured were control of inflammation, corticosteroid-sparing effects, and discontinuation of mycophenolate mofetil (including the reasons for discontinuation). Survival analysis was used to estimate the incidence of outcomes, and to identify risk factors for each. RESULTS Among 236 patients (397 eyes) treated with mycophenolate mofetil monotherapy, 20.3%, 11.9%, and 39.8% had anterior uveitis, intermediate uveitis, and posterior uveitis or panuveitis respectively; 14% had scleritis; 7.6% had mucous membrane pemphigoid; and 6.4% had other ocular inflammatory diseases. By Kaplan-Meier estimation, complete control of inflammation--sustained over consecutive visits spanning at least 28 days--was achieved in 53% and 73% of patients within 6 months and 1 year respectively. Systemic corticosteroid dosage was reduced to 10 mg of prednisone or less, while maintaining sustained control of inflammation, in 41% and 55% of patients in 6 months and 1 year respectively. Twelve percent of patients discontinued mycophenolate mofetil within the first year because of side effects of therapy. CONCLUSIONS Given sufficient time, mycophenolate mofetil was effective in managing ocular inflammation in approximately half of the treated patients. Treatment-limiting side effects were observed in 12% of patients and typically were reversible.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ajo.2009.09.026

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 257

Metadata

Authors
Daniel, E., Thorne, J. E., Newcomb, C. W., Pujari, S. S., Kaçmaz, R. O., Levy-Clarke, G. A., Nussenblatt, R. B., Rosenbaum, J. T., Suhler, E. B., Foster, C. S., Jabs, D. A., & Kempen, J. H.
Venue
American Journal of Ophthalmology
Publisher
Elsevier BV
Published
2010-03
Volume
149
Issue
3
Pages
423-432.e2
ISSN
0002-9394 (ISSN-L)
OpenAlex
W2055913604
Cited by
257
References
25
FWCI
11.72
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mycophenolate Mofetil for Ocular Inflammation. https://app.cochat.ai/papers/10.1016/j.ajo.2009.09.026
The paper
Daniel, E., Thorne, J. E., Newcomb, C. W., Pujari, S. S., Kaçmaz, R. O., Levy-Clarke, G. A., Nussenblatt, R. B., Rosenbaum, J. T., Suhler, E. B., Foster, C. S., Jabs, D. A., & Kempen, J. H. (2010). Mycophenolate Mofetil for Ocular Inflammation. American Journal of Ophthalmology. https://doi.org/10.1016/j.ajo.2009.09.026

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.